Enlivex Therapeutics Ltd.
Tel Aviv Stock Exchange ENLV.TA
Enlivex Therapeutics Ltd. Shares (Diluted, Weighted) for the year ending December 31, 2023: 18,574,484
Enlivex Therapeutics Ltd. Shares (Diluted, Weighted) is 18,574,484 for the year ending December 31, 2023, a 0.98% change year over year. Shares (diluted, weighted) are the number of outstanding shares used to calculate earnings per share (EPS) assuming the conversion of all potentially dilutive securities.
-
Enlivex Therapeutics Ltd. Shares (Diluted, Weighted) for the year ending December 31, 2022 was 18,394,886, a 3.00% change year over year.
-
Enlivex Therapeutics Ltd. Shares (Diluted, Weighted) for the year ending December 31, 2021 was 17,859,713, a 35.62% change year over year.
-
Enlivex Therapeutics Ltd. Shares (Diluted, Weighted) for the year ending December 31, 2020 was 13,169,208, a 52.25% change year over year.
-
Enlivex Therapeutics Ltd. Shares (Diluted, Weighted) for the year ending December 31, 2019 was 8,649,486, a 146.47% change year over year.
Key data
| Date | Shares (Diluted, Weighted) | Revenue | Cost of Revenue | Gross Profit |
|---|
Market news
Loading...
Tel Aviv Stock Exchange: ENLV.TA
| CEO | Dr. Oren Hershkovitz Ph.D. |
| IPO Date | July 22, 2019 |
| Location | Israel |
| Headquarters | 14 Einstein Street |
| Employees | 77 |
| Sector | Health Care |
| Industries | |
Description
Enlivex Therapeutics Ltd. operates as a clinical-stage macrophage reprogramming immunotherapy company. It is developing Allocetra, a cell-based therapy to treat organ dysfunction and failure associated with sepsis that is in phase II clinical trial, as well as in preclinical trial to treat solid tumors. The company has a collaboration agreement with BeiGene to evaluate the safety and efficacy of Allocetra in combination with tislelizumab, an anti-PD-1 immune checkpoint inhibitor for the treatment of patients with advanced-stage solid tumors. Enlivex Therapeutics Ltd. is headquartered in Ness Ziona, Israel.
Key trends
Past 5 years
StockViz Staff
January 15, 2025
Any question? Send us an email